Nucl Med Mol Imaging.
2019 Jun;53(3):208-215. 10.1007/s13139-019-00593-y.
Use of Molecular Imaging in Clinical Drug Development: a Systematic Review
- Affiliations
-
- 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, 103 Daehak-ro, Jongno-gu, 110-799 Seoul, Republic of Korea. howardlee@snu.ac.kr
- 2Center for Clinical Pharmacology, Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Jeonbuk, Republic of Korea.
- 3Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
- 4Department of Nuclear Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- 5Department of Nuclear Medicine & Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
- KMID: 2450011
- DOI: http://doi.org/10.1007/s13139-019-00593-y
Abstract
- BACKGROUND
Molecular imaging such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) can provide the crucial pharmacokinetic-pharmacodynamic information of a drug non-invasively at an early stage of clinical drug development. Nevertheless, not much has been known how molecular imaging has been actually used in drug development studies.
METHODS
We searched PubMed using such keywords as molecular imaging, PET, SPECT, drug development, and new drug, or any combination of those to select papers in English, published from January 1, 1990, to December 31, 2015. The information about the publication year, therapeutic area of a drug candidate, drug development phase, and imaging modality and utility of imaging were extracted.
RESULTS
Of 10,264 papers initially screened, 208 papers met the eligibility criteria. The more recent the publication year, the bigger the number of papers, particularly since 2010. The two major therapeutic areas using molecular imaging to develop drugs were oncology (47.6%) and the central nervous system (CNS, 36.5%), in which efficacy (63.5%) and proof-of-concept through either receptor occupancy (RO) or other than RO (29.7%), respectively, were the primary utility of molecular imaging. PET was used 4.7 times more frequently than SPECT. Molecular imaging was most frequently used in phase I clinical trials (40.8%), whereas it was employed rarely in phase 0 or exploratory IND studies (1.4%).
CONCLUSIONS
The present study confirmed the trend that molecular imaging has been more actively employed in recent clinical drug development studies although its adoption was rather slow and rare in phase 0 studies.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- MicroSPECT and MicroPET Imaging of Small Animals for Drug Development
- Ethical and Regulatory Problems of Molecular Imaging
- Deep Learning in Nuclear Medicine and Molecular Imaging: Current Perspectives and Future Directions
- Click Reaction: An Applicable Radiolabeling Method for Molecular Imaging
- Molecular Imaging in the Era of Personalized Medicine
